No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
8,000,000
September 2017
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors
Bioblast Pharma Ltd.
News
BioBlast to acquire Enlivex Therapeutics in all-stock deal
Douglas W. House
Web
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
BioSpace
November 17, 2020
BioSpace
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today announced that Brian Schwartz, MD, who served for twelve years as Chief Medical Officer of ArQule, Inc. and led ArQule's research and development programs through its $2.7 billion acquisition by Merck earlier this year, joined the Enlivex Board of Directors on November, 15, 2020.
BioSpace
November 5, 2020
BioSpace
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering methods of using AllocetraTM, the company's immunotherapy product candidate. Upon issuance, the new patent will provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases com
Alex Keown
November 5, 2020
BioSpace
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Is a
Company attributes
Location
Crunchbase
Date incorporated
October 1, 2005
Investors
Total funding amount (USD)
8,000,000
Latest funding round date
September 2017
